168 related articles for article (PubMed ID: 12600446)
1. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
Hotz HG; Hines OJ; Hotz B; Foitzik T; Buhr HJ; Reber HA
J Gastrointest Surg; 2003 Feb; 7(2):220-7; discussion 227-8. PubMed ID: 12600446
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.
Hotz HG; Gill PS; Masood R; Hotz B; Buhr HJ; Foitzik T; Hines OJ; Reber HA
J Gastrointest Surg; 2002; 6(2):159-66; discussion 166. PubMed ID: 11992800
[TBL] [Abstract][Full Text] [Related]
3. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.
Hotz HG; Hines OJ; Masood R; Hotz B; Foitzik T; Buhr HJ; Gill PS; Reber HA
Surgery; 2005 Feb; 137(2):192-9. PubMed ID: 15674201
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
Hotz HG; Reber HA; Hotz B; Sanghavi PC; Yu T; Foitzik T; Buhr HJ; Hines OJ
J Gastrointest Surg; 2001; 5(2):131-8. PubMed ID: 11331474
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer.
Zervox EE; Franz MG; Salhab KF; Shafii AE; Menendez J; Gower WR; Rosemurgy AS
J Gastrointest Surg; 2000; 4(6):614-9. PubMed ID: 11307097
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.
Zervos EE; Norman JG; Gower WR; Franz MG; Rosemurgy AS
J Surg Res; 1997 May; 69(2):367-71. PubMed ID: 9224409
[TBL] [Abstract][Full Text] [Related]
9. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis.
Silvestre JS; Mallat Z; Tamarat R; Duriez M; Tedgui A; Levy BI
Circ Res; 2001 Aug; 89(3):259-64. PubMed ID: 11485976
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Belotti D; Paganoni P; Manenti L; Garofalo A; Marchini S; Taraboletti G; Giavazzi R
Cancer Res; 2003 Sep; 63(17):5224-9. PubMed ID: 14500349
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
12. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.
Borgström P; Bourdon MA; Hillan KJ; Sriramarao P; Ferrara N
Prostate; 1998 Apr; 35(1):1-10. PubMed ID: 9537593
[TBL] [Abstract][Full Text] [Related]
14. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix.
Collen A; Hanemaaijer R; Lupu F; Quax PH; van Lent N; Grimbergen J; Peters E; Koolwijk P; van Hinsbergh VW
Blood; 2003 Mar; 101(5):1810-7. PubMed ID: 12393408
[TBL] [Abstract][Full Text] [Related]
15. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control.
Jimenez RE; Hartwig W; Antoniu BA; Compton CC; Warshaw AL; Fernández-Del Castillo C
Ann Surg; 2000 May; 231(5):644-54. PubMed ID: 10767785
[TBL] [Abstract][Full Text] [Related]
16. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.
Haq M; Shafii A; Zervos EE; Rosemurgy AS
Cancer Res; 2000 Jun; 60(12):3207-11. PubMed ID: 10866312
[TBL] [Abstract][Full Text] [Related]
17. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis.
Muhs BE; Patel S; Yee H; Marcus S; Shamamian P
J Surg Res; 2003 Feb; 109(2):110-7. PubMed ID: 12643851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]